Full Value of Vaccine Assessments (FVVA)
The pathway from vaccine product concept, through development, licensure and deployment is costly and inherently risky for manufacturers, particularly for vaccines against diseases where the burden is predominantly in LMICs. A description of
the process from vaccine development to WHO policy recommendation can be found here:
In resource-constrained settings, an increasingly compelling rationale will be needed to justify the inclusion of these new vaccines within immunization programs, over and above many other priorities. As such, the ability to guarantee the global demand, and the willingness to procure at the end of a costly product development pathway is uncertain, and vaccine manufacturers often prioritize high-income markets that offer a more immediate return on investment. The result can be a delay between vaccine licensure and access to these vaccines by low- and middle-income countries (LMICs), where there is the greatest public health need.
To reduce the uncertainty in investment and inform potential introduction decisions, IVB has developed a framework and methodology to broaden the evaluation of ‘vaccine value’ beyond solely the demonstration of individual health benefits, to include broader socioeconomic and indirect impact(s) that the vaccine could have. This concept is known as the ‘Full Vaccine Value Assessment’ or FVVA, and is considered a critical analysis to inform prioritization for investment and eventual uptake. WHO has developed a framework to assess and communicate the FVVA, accessible at the link below.
PDR is in the process of developing FVVAs related to a number of infectious diseases. When available, pathogen-specific FVVAs can be accessed through the IVB disease pages through the link below.